AbCellera Biologics (ABCL) Free Cash Flow (2020 - 2026)

AbCellera Biologics has reported Free Cash Flow for 7 years, with the latest figure at -$37.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 68.34% year-over-year to -$37.4 million; the trailing twelve-month figure through Mar 2026 stood at -$189.2 million (down 32.06% YoY), and the FY2025 full-year result was -$174.1 million, up 6.89% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$37.4 million, up from -$44.6 million in the prior quarter.
• The five-year high for Free Cash Flow was $241.7 million in Q2 2022, with the low at -$139.3 million in Q3 2022.
• Historically, Free Cash Flow has averaged -$18.4 million across 5 years, with a median of -$37.4 million in 2026.
• The largest YoY upside for Free Cash Flow was 171.08% in 2022 against a maximum downside of 860.29% in 2022.
• AbCellera Biologics' Free Cash Flow stood at $18.6 million in 2022, then tumbled by 283.2% to -$34.0 million in 2023, then soared by 30.59% to -$23.6 million in 2024, then plunged by 88.68% to -$44.6 million in 2025, then advanced by 16.22% to -$37.4 million in 2026.
• The last three Free Cash Flow figures came in at -$37.4 million (Q1 2026), -$44.6 million (Q4 2025), and -$61.5 million (Q3 2025), per Business Quant data.